More Than 100 Applications Lost Equivalence Rating Thanks To Allegedly Falsified Data At Two CROs
Executive Summary
Sponsors must decide whether to repeat bioequivalence and other studies after two CROs were found to have potentially falsified data, causing the US FDA to reject all data produced by the firms.
You may also be interested in...
Will US FDA Offer Regulatory Flexibility For ANDAs Downgraded Because Of CRO Investigation?
Complex generic may have some wiggle room, but the only choice for many sponsors may be to redo the affected studies or withdraw the products that have lost bioequivalence status after FDA questioned the integrity of the data from two contract researchers.
Data Integrity: COVID-19 Impacted Studies Pose Unique Enforcement Risks
Move toward decentralized trials means sponsors may be working with naïve clinical investigators who lack experience, Greenleaf’s Cynthia Schnedar says; DoJ’s Gustav Eyler urges drug sponsors to look for oddities in clinical trial data and to voluntarily report potential misconduct.
Generic Industry’s Future May Include A Role In The Gene Therapy Space
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.